PRESCRIPTION AND USE OF LIPOSOMAL AMPHOTERICIN B DURING THE COVID-19 PANDEMIC

P. BLANCO GARCIA1, M. ANTON MARTINEZ2, A. FIJÓ PRIETO1, M.T. SÁNCHEZ SÁNCHEZ1
1HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID, HOSPITAL PHARMACY, VALLADOLID, SPAIN.

BACKGROUND AND IMPORTANCE
✓ The impact of Covid-19 and its influence in the management of hospitalized patients has been indisputable. Many publications present combinations of different antimicrobials to treat the patients infections, and the Liposomal Amphotericin B (Amb-L) is an example of one of the most prescribed.

AIM AND OBJECTIVES
✓ To compare the prescription and indication of AmB-L in a tertiary care hospital before and during the Covid-19 pandemic.

MATERIAL AND METHODS
✓ Descriptive study of patients prescribed AmB-L
✓ Observational
✓ Retrospective

RESULTS
✓ March 2020 to March 2021
- Total number of patients
  - 17
  - 56
- Women
  - 5
  - 18
- Men
  - 17
  - 38
- Median age
  - 53 years [IQR: 38.2-59.1]
  - 63.5 years [IQR: 49.5-71.25]

CONCLUSION AND RELEVANCE
✓ The prescription is tripled during the observed period in all the described fields.
✓ Critical patients profile: unstable, risk factors and with higher doses of AmB-L.
✓ It is necessary to optimize the use of Amb-L to guarantee efficiency and pharmaceutical spending.

J02 ANTIMYCOTICS FOR SYSTEMIC USE
No conflict of interest
6ER-020.